Clinical trial NCT02295865 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: jnj-38518168 60 mg, jnj-38518168 30 mg, jnj-38518168 3 mg, placebo
SMILES: CN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1, CN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1, CN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant must have a diagnosis of plaque-type psoriasis (with or without psoriatic
             arthritis [PsA]) for at least 6 months before the first administration of study drug

          -  Participant must have a Psoriasis Area and Severity Index (PASI) Greater Than or equal
             to (>=) 12 at screening and at baseline

          -  Participant must have an Investigator's Global Assessment (IGA) >=3 at screening and
             at baseline

          -  A woman of childbearing potential must have a negative urine pregnancy test at
             screening and at Week 0

          -  A man who is sexually active with a woman of childbearing potential and has not had a
             vasectomy must agree to use a barrier method of birth control during the study and for
             4 months after receiving the last administration of study drug. All men must also
             agree to not donate sperm during the study and for 4 months after receiving the last
             administration of study drug

        Exclusion Criteria:

          -  Participant has a history or current signs or symptoms of severe, progressive, or
             uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary,
             cardiac, neurologic, cerebral, or psychiatric disease

          -  Participant has a current malignancy or history of malignancy within 5 years before
             screening (with the exception of a nonmelanoma skin cancer that has been adequately
             treated with no evidence of recurrence for at least 3 months before the first study
             drug administration, or cervical carcinoma in situ that has been treated with no
             evidence of recurrence for at least 1 year before the first study drug administration)

          -  Participant has a history of lymphoproliferative disease, including lymphoma; a
             history of monoclonal gammopathy of undetermined significance (MGUS); or signs and
             symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy
             or splenomegaly

          -  Participant has a history of chronic or recurrent infectious disease, including but
             not limited to chronic renal infection, chronic chest infection (eg, bronchiectasis),
             recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting
             cystitis), fungal infection (mucocutaneous candidiasis), or open, draining, or
             infected skin wounds or ulcers

          -  Participant has a history of an infected joint prosthesis, or has received antibiotics
             for a suspected infection of a joint prosthesis, if that prosthesis has not been
             removed or replaced

          -  Participant has ever received any previous biologic therapy for psoriasis or psoriatic
             arthritis